Dynamic differences in dietary polyunsaturated fatty acid metabolism in sputum of COPD patients and controls.

[1]  C. Pilette,et al.  Aberrant epithelial differentiation by cigarette smoke dysregulates respiratory host defence , 2018, European Respiratory Journal.

[2]  C. Serhan,et al.  Lipid Mediator Metabolomics Via LC-MS/MS Profiling and Analysis. , 2018, Methods in molecular biology.

[3]  M. Giera,et al.  Isoprostanes, neuroprostanes and phytoprostanes: An overview of 25years of research in chemistry and biology. , 2017, Progress in lipid research.

[4]  M. Giera,et al.  Targeted lipidomics reveals activation of resolution pathways in knee osteoarthritis in humans. , 2017, Osteoarthritis and cartilage.

[5]  C. Serhan.  Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms , 2017, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[6]  Z. Djuric,et al.  Pathway Markers for Pro-resolving Lipid Mediators in Maternal and Umbilical Cord Blood: A Secondary Analysis of the Mothers, Omega-3, and Mental Health Study , 2016, Front. Pharmacol..

[7]  Manuel C. Peitsch,et al.  Alterations in Serum Polyunsaturated Fatty Acids and Eicosanoids in Patients with Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD) , 2016, International journal of molecular sciences.

[8]  B. Levy,et al.  DHA- and EPA-derived resolvins, protectins, and maresins in airway inflammation. , 2016, European journal of pharmacology.

[9]  C. Serhan,et al.  Resolvin D1 Reduces Emphysema and Chronic Inflammation. , 2015, The American journal of pathology.

[10]  C. Serhan,et al.  Resolvins attenuate inflammation and promote resolution in cigarette smoke-exposed human macrophages. , 2015, American journal of physiology. Lung cellular and molecular physiology.

[11]  D. Romberger,et al.  Maresin-1 reduces airway inflammation associated with acute and repetitive exposures to organic dust. , 2015, Translational research : the journal of laboratory and clinical medicine.

[12]  P. Klenerman,et al.  Prostaglandin D2 and leukotriene E4 synergize to stimulate diverse TH2 functions and TH2 cell/neutrophil crosstalk , 2015, The Journal of allergy and clinical immunology.

[13]  W. Willett,et al.  Alternate Healthy Eating Index 2010 and risk of chronic obstructive pulmonary disease among US women and men: prospective study , 2015, BMJ : British Medical Journal.

[14]  M. Giera,et al.  An Advanced LC–MS/MS Platform for the Analysis of Specialized Pro-Resolving Lipid Mediators , 2015, Chromatographia.

[15]  P. Bakke,et al.  Comparison of inflammatory markers in induced and spontaneous sputum in a cohort of COPD patients , 2014, Respiratory Research.

[16]  Charles N. Serhan,et al.  Pro-resolving lipid mediators are leads for resolution physiology , 2014, Nature.

[17]  M. Sanak,et al.  Eicosanoid biosynthesis during mucociliary and mucous metaplastic differentiation of bronchial epithelial cells. , 2013, Prostaglandins & other lipid mediators.

[18]  Modification of the fatty acid composition of the erythrocyte membrane in patients with chronic respiratory diseases , 2013, Lipids in Health and Disease.

[19]  C. Serhan,et al.  A Novel Anti-Inflammatory and Pro-Resolving Role for Resolvin D1 in Acute Cigarette Smoke-Induced Lung Inflammation , 2013, PloS one.

[20]  S. Gangopadhyay,et al.  Lipids of Erythrocyte Membranes of COPD Patients: A Quantitative and Qualitative Study , 2012, COPD.

[21]  L. Lanza,et al.  Epidemiology of chronic obstructive pulmonary disease: a literature review , 2012, International journal of chronic obstructive pulmonary disease.

[22]  B. Samuelsson.  Role of Basic Science in the Development of New Medicines: Examples from the Eicosanoid Field , 2012, The Journal of Biological Chemistry.

[23]  G. Hejblum,et al.  Variability of the chronic obstructive pulmonary disease key epidemiological data in Europe: systematic review , 2011, BMC medicine.

[24]  P. Bakke,et al.  Body composition and plasma levels of inflammatory biomarkers in COPD , 2010, European Respiratory Journal.

[25]  R. Louis,et al.  Leukotriene B4 contributes to exhaled breath condensate and sputum neutrophil chemotaxis in COPD. , 2009, Chest.

[26]  P. Bakke,et al.  Systemic inflammatory markers in COPD: results from the Bergen COPD Cohort Study , 2009, European Respiratory Journal.

[27]  K. Kubo,et al.  Enhanced levels of prostaglandin E2 and matrix metalloproteinase‐2 correlate with the severity of airflow limitation in stable COPD , 2008, Respirology.

[28]  A. Folsom,et al.  Dietary n-3 polyunsaturated acids and smoking-related chronic obstructive pulmonary disease. , 2008, American journal of epidemiology.

[29]  P. Burney,et al.  The relation between dietary intake of individual fatty acids, FEV1 and respiratory disease in Dutch adults , 2007, Thorax.

[30]  J. Uddin,et al.  Resolvin D1 and Its Aspirin-triggered 17R Epimer , 2007, Journal of Biological Chemistry.

[31]  J. Wallace,et al.  Resolution of in flammation: state of the art, definitions and terms , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[32]  Yorihiro Yamamoto,et al.  Reduction in plasma free fatty acid in patients with chronic obstructive pulmonary disease. , 2005, American journal of respiratory and critical care medicine.

[33]  D. Postma,et al.  The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation , 2004, European Respiratory Journal.

[34]  I. Rubinstein,et al.  Long-term montelukast therapy in moderate to severe COPD--a preliminary observation. , 2004, Respiratory medicine.

[35]  P. Montuschi,et al.  CT-guided pleural biopsy preferable to traditional Abram’s needle in diagnosing malignant pleural disease , 2003, Thorax.

[36]  A. Nissinen,et al.  Diet and 20-year chronic obstructive pulmonary disease mortality in middle-aged men from three European countries , 2002, European Journal of Clinical Nutrition.

[37]  Kai Yu,et al.  Differential Activation of Peroxisome Proliferator-activated Receptors by Eicosanoids (*) , 1995, The Journal of Biological Chemistry.

[38]  R. Murphy,et al.  Eosinophil 15-lipoxygenase is a leukotriene A4 synthase. , 1994, The Journal of biological chemistry.

[39]  E. R. Mcfadden,et al.  Bronchoconstrictor effects of leukotriene E4 in normal and asthmatic subjects. , 1987, The American review of respiratory disease.